A Study to Assess the Efficacy and Safety of Namilumab in Participants With Chronic Pulmonary Sarcoidosis

NCT05314517 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

107

Enrollment

INDUSTRY

Sponsor class

Stopped Sponsor Decision

Conditions

Sarcoidosis, Pulmonary

Interventions

DRUG: Namilumab
DRUG: Placebo

Sponsor

Kinevant Sciences GmbH